Clinical Features, STAT3 Gene Mutations and Th17 Cell Analysis in Nine Children with Hyper‐IgE Syndrome in Mainland China

Hyper‐IgE syndrome (HIES) is a rare primary immunodeficiency disease characterized by eczema, recurrent staphylococcal aureus skin abscesses, pneumonia with pneumatocele formation, remarkably high serum IgE levels, eosinophilia and involvement of skeleton and connective tissues. Heterozygous signal...

Full description

Saved in:
Bibliographic Details
Published inScandinavian journal of immunology Vol. 78; no. 3; pp. 258 - 265
Main Authors Zhang, L.‐Y., Tian, W., Shu, L., Jiang, L.‐P., Zhan, Y.‐Z., Liu, W., Zhao, X.‐D., Cui, Y.‐X., Tang, X.‐M., Wang, M., Wu, D.‐Q., Yang, X.‐Q.
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.09.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Hyper‐IgE syndrome (HIES) is a rare primary immunodeficiency disease characterized by eczema, recurrent staphylococcal aureus skin abscesses, pneumonia with pneumatocele formation, remarkably high serum IgE levels, eosinophilia and involvement of skeleton and connective tissues. Heterozygous signal transducer and activator of transcription 3 (STAT3) mutations were shown to be the cause of autosomal dominant HIES (AD‐HIES). In this study, we diagnosed nine patients with HIES from 9 unrelated families on the basis of a National Institutes of Health (NIH) score of ≥40 points, sequenced the STAT3 gene of all nine patients, and quantified Th17 cells in peripheral blood of seven patients by flow cytometry in mainland China. All nine patients had characteristic manifestation of HIES with the range of NIH scores 45–77 points. STAT3 hot mutations V637M or R382W/Q were identified in five patients. We identified two novel heterozygous missense mutations (T620S and R609G) located in Src homology 2 (SH2) domain in two patients, respectively. In two other patients, no STAT3 mutations were found. Quantified Th17 cell numbers were markedly decreased or absent (0–0.28% of CD4+T cells) in six patients with STAT3 mutations and almost normal (0.53% of CD4+T cells) in one wild‐type STAT3 patient compared with healthy controls (0.40–2.25% of CD4+T cells). These results suggest that not all patients with HIES who had NIH scores over 40 points carry STAT3 mutations, those whose Th17 cell numbers strikingly decreased probably had AD‐HIES with STAT3 mutations.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0300-9475
1365-3083
DOI:10.1111/sji.12063